MCID: OLG002
MIFTS: 67

Oligodendroglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 12 53 59 29 55 6 44 15 17 72
Oligodendroglial Neoplasm 12 72
Oligodendroglial Tumor 12 59
Well Differentiated Oligodendroglioma 72
Oligodendroglial Tumors 55

Characteristics:

Orphanet epidemiological data:

59
oligodendroglioma
Inheritance: Not applicable; Age of onset: All ages;
oligodendroglial tumor
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3181
MeSH 44 D009837
SNOMED-CT 68 73348003
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 73 C0028945
UMLS 72 C0028945 C0751396 C1335110

Summaries for Oligodendroglioma

NIH Rare Diseases : 53 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. They tend to grow slowly and may be present for many years before they are diagnosed. Common symptoms include seizures, headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q. Treatment generally involves surgical removal of the tumor followed by radiation therapy and/or chemotherapy. Recurrent tumors may need additional surgery, radiation and chemotherapy.

MalaCards based summary : Oligodendroglioma, also known as oligodendroglial neoplasm, is related to adult oligodendroglioma and childhood oligodendroglioma. An important gene associated with Oligodendroglioma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and temporal lobe, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 75 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 369)
# Related Disease Score Top Affiliating Genes
1 adult oligodendroglioma 35.0 IDH2 IDH1
2 childhood oligodendroglioma 34.6 TP73 SYP OLIG2 IDH1 GFAP
3 oligoastrocytoma 34.4 MGMT IDH2 GFAP
4 glioma susceptibility 1 34.2 TP53 IDH2 IDH1 GFAP
5 anaplastic oligodendroglioma 33.9 POT1 MGMT IDH2 GFAP EGFR CDKN2C
6 glioma 32.5 TP53 PTEN POT1 IDH2 IDH1 EGFR
7 dysembryoplastic neuroepithelial tumor 31.9 SYP IDH1 GFAP
8 mixed glioma 31.7 TP53 IDH1 GFAP
9 extraventricular neurocytoma 31.6 SYP IDH1 GFAP
10 ependymoma 31.5 TP73 SYP MGMT GFAP EGFR
11 gemistocytic astrocytoma 31.4 PTEN IDH2 GFAP
12 teratoma 31.3 TP53 SYP GFAP
13 glioblastoma multiforme 31.3 TP53 PTEN MGMT IDH1 GFAP EGFR
14 angiocentric glioma 31.2 SYP IDH1 GFAP
15 cystic teratoma 31.2 TP53 SYP GFAP
16 ganglioglioma 31.2 TP53 SYP GFAP
17 hydrocephalus 31.1 TP53 SYP PTEN MBP GFAP
18 enchondroma 31.0 IDH2 IDH1
19 meningioma, familial 31.0 TP53 SYP PTEN GFAP CDKN2A
20 anaplastic ependymoma 31.0 SYP PTEN GFAP
21 glioblastoma 30.9 TP53 PTEN MGMT IDH2 IDH1 EGFR
22 adult astrocytic tumour 30.9 PTEN IDH2 IDH1 ATRX
23 fibrillary astrocytoma 30.8 TP53 MGMT IDH2 IDH1 GFAP ATRX
24 gliomatosis cerebri 30.7 TP53 PTEN IDH1 GFAP EGFR
25 optic nerve glioma 30.7 TP53 SYP MBP GFAP
26 lynch syndrome 30.7 TP53 MGMT EGFR CDKN2A
27 cerebral neuroblastoma 30.6 TP53 SYP GFAP
28 gliosarcoma 30.6 TP53 PTEN MGMT IDH1 GFAP EGFR
29 myeloma, multiple 30.6 TP53 IDH2 IDH1 CDKN2A
30 pleomorphic xanthoastrocytoma 30.5 TP53 SYP MGMT IDH1 GFAP
31 brain glioma 30.5 TP53 MGMT IDH1 GFAP EGFR
32 cerebellar liponeurocytoma 30.5 TP53 SYP OLIG2 GFAP
33 gangliocytoma 30.5 SYP PTEN
34 central nervous system lymphoma 30.5 TP53 MGMT CDKN2A
35 juvenile pilocytic astrocytoma 30.5 TP53 MBP GFAP CDKN2A
36 nervous system disease 30.4 TP53 SYP MBP GFAP
37 li-fraumeni syndrome 30.3 TP53 PTEN IDH1 EGFR CDKN2A
38 leukemia, acute lymphoblastic 3 30.2 TP53 CDKN2B CDKN2A
39 grade iii astrocytoma 29.7 TP53 PTEN OLIG2 OLIG1 MGMT IDH2
40 medulloblastoma 29.7 TP73 TP53 SYP PTEN MGMT IDH1
41 brain cancer 29.6 TP73 TP53 SYP PTEN OLIG2 OLIG1
42 lung cancer 29.4 TP73 TP53 SYP PTEN MGMT EGFR
43 spinal cord oligodendroglioma 12.4
44 brain oligodendroglioma 12.4
45 corpus callosum oligodendroglioma 12.4
46 mixed oligodendroglioma-astrocytoma 12.4
47 mixed astrocytoma-ependymoma-oligodendroglioma 12.2
48 glial tumor 11.6
49 glioma susceptibility 2 11.2
50 glioma susceptibility 3 11.2

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CDKN2A CIC GMNN NKX2-2 POT1 PTEN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CDKN2A CIC GMNN NKX2-2 POT1 PTEN
3 Decreased viability in esophageal squamous lineage GR00235-A 9.7 CDKN2A CDKN2C CIC GFAP IDH1 IDH2

MGI Mouse Phenotypes related to Oligodendroglioma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 ATRX CDKN2A CDKN2B CDKN2C EGFR GFAP
2 behavior/neurological MP:0005386 10.36 ATRX CDKN2A CDKN2C CIC GFAP GMNN
3 mortality/aging MP:0010768 10.36 ATRX CDKN2A CDKN2B CDKN2C CIC EGFR
4 growth/size/body region MP:0005378 10.34 ATRX CDKN2A CDKN2C CIC EGFR GFAP
5 homeostasis/metabolism MP:0005376 10.27 CDKN2A CDKN2B CDKN2C EGFR GFAP GMNN
6 endocrine/exocrine gland MP:0005379 10.21 CDKN2A CDKN2B CDKN2C EGFR GMNN MGMT
7 nervous system MP:0003631 10.2 ATRX CDKN2A CDKN2C CIC EGFR GFAP
8 embryo MP:0005380 10.18 ATRX CDKN2A EGFR GMNN NKX2-2 POT1
9 hematopoietic system MP:0005397 10.18 CDKN2A CDKN2B CDKN2C EGFR GMNN IDH1
10 immune system MP:0005387 10.17 CDKN2A CDKN2B CDKN2C EGFR GFAP GMNN
11 neoplasm MP:0002006 10.07 CDKN2A CDKN2B CDKN2C EGFR IDH2 MGMT
12 reproductive system MP:0005389 9.9 ATRX CDKN2A CDKN2B CDKN2C EGFR GMNN
13 no phenotypic analysis MP:0003012 9.8 CDKN2A CDKN2B EGFR MGMT OLIG2 POT1
14 respiratory system MP:0005388 9.65 CDKN2A CDKN2C CIC EGFR IDH1 MGMT
15 vision/eye MP:0005391 9.32 ATRX CDKN2A EGFR GFAP GMNN MBP

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
9
leucovorin Approved Phase 3 58-05-9 143 6006
10
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
11
Donepezil Approved Phase 3 120014-06-4 3152
12
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
16
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
17
Histamine Approved, Investigational Phase 3 51-45-6 774
18
Cyproheptadine Approved Phase 3 129-03-3 2913
19
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
20
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Antineoplastic Agents, Phytogenic Phase 3
24 Immunosuppressive Agents Phase 3
25 Nucleic Acid Synthesis Inhibitors Phase 3
26 Antimetabolites Phase 3
27 Antimetabolites, Antineoplastic Phase 3
28 Etoposide phosphate Phase 3
29 Antirheumatic Agents Phase 3
30 Folic Acid Antagonists Phase 3
31 Vitamin B9 Phase 3
32 Folate Phase 3
33 Vitamin B Complex Phase 3
34 Liver Extracts Phase 3
35 Analgesics Phase 3
36 Central Nervous System Depressants Phase 3
37 Nootropic Agents Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Emetics Phase 3
40 Anesthetics Phase 3
41 Cholinesterase Inhibitors Phase 3
42 Cholinergic Agents Phase 3
43 Cola Phase 3
44 Anesthetics, Intravenous Phase 3
45 Narcotics Phase 3
46 Analgesics, Opioid Phase 3
47 Adjuvants, Anesthesia Phase 3
48 Anesthetics, General Phase 3
49 Tubulin Modulators Phase 3
50 Antimitotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 373)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
4 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
5 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
7 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
9 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
10 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
11 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
14 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
15 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
16 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
17 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
18 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
19 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
21 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
22 A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas Unknown status NCT00004204 Phase 2 temozolomide
23 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
24 A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
25 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
26 A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours Unknown status NCT03216148 Phase 2
27 Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma Unknown status NCT00892177 Phase 2 dasatinib
28 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
29 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
30 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
31 Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
32 First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial Completed NCT00003731 Phase 2 temozolomide
33 Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy Completed NCT00003304 Phase 2 temozolomide
34 Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal Completed NCT00003466 Phase 2 temozolomide
35 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
36 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
37 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
38 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
39 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
40 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
41 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
42 Immunotherapy for Malignant Glioma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy Completed NCT00004024 Phase 2
43 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
44 Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
45 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas Completed NCT00575887 Phase 2 Temozolomide
47 Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Completed NCT00717197 Phase 2 Capecitabine
48 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
49 Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers Completed NCT00003467 Phase 2 carmustine;polifeprosan 20 with carmustine implant
50 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin

Search NIH Clinical Center for Oligodendroglioma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Procarbazine

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 29

Anatomical Context for Oligodendroglioma

MalaCards organs/tissues related to Oligodendroglioma:

41
Brain, Spinal Cord, Temporal Lobe, Bone, T Cells, Endothelial, Bone Marrow

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 2641)
# Title Authors PMID Year
1
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. 9 38
19967449 2010
2
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. 9 38
20052522 2009
3
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 9 38
19934553 2009
4
[Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis]. 9 38
19618851 2009
5
[Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. 9 38
19781190 2009
6
Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. 9 38
19357963 2009
7
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 9 38
19346643 2009
8
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. 9 38
19240607 2009
9
[Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors]. 9 38
19663312 2009
10
Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study. 9 38
18774492 2008
11
[Radiotherapy of adult glial tumors: new developments and perspectives]. 9 38
18565351 2008
12
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. 9 38
18552083 2008
13
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. 9 38
17435181 2007
14
Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis. 9 38
17867825 2007
15
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 9 38
17415208 2007
16
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 9 38
17319279 2007
17
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. 9 38
17146289 2006
18
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. 9 38
16874663 2006
19
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. 9 38
16541434 2006
20
Survival analysis of presumptive prognostic markers among oligodendrogliomas. 9 38
16116609 2005
21
OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. 9 38
16103065 2005
22
Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours. 9 38
16202357 2005
23
Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines. 9 38
15968641 2005
24
Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. 9 38
15899783 2005
25
Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. 9 38
16038527 2005
26
Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. 9 38
15834925 2005
27
Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas. 9 38
15711769 2005
28
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 9 38
15455350 2005
29
Gene expression profiling and subgroup identification of oligodendrogliomas. 9 38
15208679 2004
30
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. 9 38
15118874 2004
31
p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. 9 38
15269478 2004
32
Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. 9 38
15086520 2004
33
Transcriptional regulation of the human UDP-galactose:ceramide galactosyltransferase (hCGT) gene expression: functional role of GC-box and CRE. 9 38
15229398 2004
34
Heterogeneity in the expression of markers for drug resistance in brain tumors. 9 38
14986930 2004
35
Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. 9 38
14507338 2003
36
Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans. 9 38
12873740 2003
37
Genetic determinants of malignancy in a mouse model for oligodendroglioma. 9 38
12670909 2003
38
CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. 9 38
12556968 2003
39
Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. 9 38
12507133 2002
40
Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. 9 38
12168841 2002
41
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. 9 38
11929835 2002
42
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. 9 38
11801559 2002
43
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome. 9 38
11800646 2002
44
Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. 9 38
11557779 2001
45
Mutation analysis of the p73 gene in nonastrocytic brain tumours. 9 38
11461077 2001
46
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas. 9 38
11419973 2001
47
Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. 9 38
11322447 2001
48
Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. 9 38
11307615 2001
49
Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures. 9 38
11170177 2001
50
Characterization of the human UDP-galactose:ceramide galactosyltransferase gene promoter. 9 38
11342220 2001

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 IDH1 NM_005896.3(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
2 CIC NM_015125.4(CIC): c.290_291insT (p.Gly99fs) insertion Likely pathogenic 19:42791230-42791231 19:42287078-42287079
3 ATRX NM_000489.5(ATRX): c.4213A> G (p.Arg1405Gly) single nucleotide variant Uncertain significance X:76912051-76912051 X:77656561-77656561

Cosmic variations for Oligodendroglioma:

9 (show top 50) (show all 6891)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6959574 ZRSR2 central nervous system,brain,glioma,anaplastic c.260G>A p.R87K 23:15803744-15803744 4
2 COSM6973162 ZRSR2 central nervous system,brain,glioma,oligodendroglioma Grade III c.220G>A p.E74K 23:15803704-15803704 4
3 COSM6950242 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.8300G>A p.G2767E 16:72794382-72794382 4
4 COSM6959528 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 4
5 COSM6980194 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.6025T>C p.Y2009H 16:72796657-72796657 4
6 COSM5981027 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 4
7 COSM6973145 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.3986G>A p.G1329E 16:72798696-72798696 4
8 COSM6976663 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.8600C>T p.S2867F 16:72794082-72794082 4
9 COSM6968504 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.2680G>A p.D894N 16:72957466-72957466 4
10 COSM6968503 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.9154G>A p.V3052I 16:72793528-72793528 4
11 COSM6919634 YES1 central nervous system,brain,glioma,oligodendroglioma Grade III c.259G>C p.A87P 18:756569-756569 4
12 COSM6912189 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 4
13 COSM2178900 VTCN1 central nervous system,brain,glioma,anaplastic c.404C>T p.S135F 1:117156615-117156615 4
14 COSM6973140 TSHR central nervous system,brain,glioma,oligodendroglioma Grade III c.1560G>A p.W520* 14:81143618-81143618 4
15 COSM6969075 TSHR central nervous system,brain,glioma,anaplastic c.1493G>A p.G498D 14:81143551-81143551 4
16 COSM6968495 TSHR central nervous system,brain,glioma,oligodendroglioma Grade III c.1765C>T p.L589F 14:81143823-81143823 4
17 COSM6916888 TSC2 central nervous system,brain,glioma,oligodendroglioma Grade III c.3131G>A p.R1044K 16:2079196-2079196 4
18 COSM6969076 TSC2 central nervous system,brain,glioma,anaplastic c.3124C>T p.P1042S 16:2079189-2079189 4
19 COSM6946774 TSC2 central nervous system,brain,glioma,anaplastic c.574G>T p.D192Y 16:2055494-2055494 4
20 COSM6942687 TSC1 central nervous system,brain,glioma,oligodendroglioma Grade III c.1525C>T p.R509* 9:132906053-132906053 4
21 COSM6959458 TSC1 central nervous system,brain,glioma,anaplastic c.913+1G>A p.? 9:132912281-132912281 4
22 COSM6968499 TRAF7 central nervous system,brain,glioma,oligodendroglioma Grade III c.1189G>A p.G397S 16:2173974-2173974 4
23 COSM6936579 TRAF7 central nervous system,brain,glioma,oligodendroglioma Grade III c.1898T>C p.M633T 16:2176284-2176284 4
24 COSM6962789 TP63 central nervous system,brain,glioma,oligodendroglioma Grade III c.437C>T p.P146L 3:189808384-189808384 4
25 COSM10648 TP53 central nervous system,brain,glioma,anaplastic c.524G>A p.R175H 17:7675088-7675088 4
26 COSM10790 TP53 central nervous system,brain,glioma,anaplastic c.455C>T p.P152L 17:7675157-7675157 4
27 COSM11224 TP53 central nervous system,brain,glioma,anaplastic c.394A>C p.K132Q 17:7675218-7675218 4
28 COSM43708 TP53 central nervous system,brain,glioma,oligodendroglioma Grade III c.422G>A p.C141Y 17:7675190-7675190 4
29 COSM44829 TP53 central nervous system,brain,glioma,anaplastic c.403T>G p.C135G 17:7675209-7675209 4
30 COSM43748 TP53 central nervous system,brain,glioma,anaplastic c.783T>C p.S261S 17:7673837-7673837 4
31 COSM10660 TP53 central nervous system,brain,glioma,anaplastic c.818G>A p.R273H 17:7673802-7673802 4
32 COSM44693 TP53 central nervous system,brain,glioma,anaplastic c.707A>C p.Y236S 17:7674256-7674256 4
33 COSM11133 TP53 central nervous system,brain,glioma,anaplastic c.725G>C p.C242S 17:7674238-7674238 4
34 COSM10654 TP53 central nervous system,brain,glioma,anaplastic c.637C>T p.R213* 17:7674894-7674894 4
35 COSM10663 TP53 central nervous system,brain,glioma,anaplastic c.916C>T p.R306* 17:7673704-7673704 4
36 COSM43697 TP53 central nervous system,brain,glioma,anaplastic c.832C>A p.P278T 17:7673788-7673788 4
37 COSM44249 TP53 central nervous system,brain,glioma,oligodendroglioma Grade III c.623A>T p.D208V 17:7674908-7674908 4
38 COSM10768 TP53 central nervous system,brain,glioma,anaplastic c.535C>T p.H179Y 17:7675077-7675077 4
39 COSM43742 TP53 central nervous system,brain,glioma,anaplastic c.419C>T p.T140I 17:7675193-7675193 4
40 COSM44240 TP53 central nervous system,brain,glioma,anaplastic c.514G>T p.V172F 17:7675098-7675098 4
41 COSM44327 TP53 central nervous system,brain,glioma,anaplastic c.518T>C p.V173A 17:7675094-7675094 4
42 COSM10891 TP53 central nervous system,brain,glioma,anaplastic c.814G>A p.V272M 17:7673806-7673806 4
43 COSM46287 TP53 central nervous system,brain,glioma,anaplastic c.557A>G p.D186G 17:7675055-7675055 4
44 COSM10645 TP53 central nervous system,brain,glioma,anaplastic c.527G>T p.C176F 17:7675085-7675085 4
45 COSM10651 TP53 central nervous system,brain,glioma,anaplastic c.530C>G p.P177R 17:7675082-7675082 4
46 COSM10777 TP53 central nervous system,brain,glioma,anaplastic c.715A>G p.N239D 17:7674248-7674248 4
47 COSM43545 TP53 central nervous system,brain,glioma,anaplastic c.503A>G p.H168R 17:7675109-7675109 4
48 COSM44945 TP53 central nervous system,brain,glioma,anaplastic c.672G>C p.E224D 17:7674859-7674859 4
49 COSM11188 TP53 central nervous system,brain,glioma,anaplastic c.412G>C p.A138P 17:7675200-7675200 4
50 COSM10750 TP53 central nervous system,brain,glioma,anaplastic c.490A>T p.K164* 17:7675122-7675122 4

Copy number variations for Oligodendroglioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 12.73 TP53 PTEN EGFR CDKN2B CDKN2A
2
Show member pathways
12.62 TP53 PTEN EGFR CDKN2B CDKN2A
3
Show member pathways
12.48 TP53 PTEN EGFR CDKN2C CDKN2B CDKN2A
4
Show member pathways
12.26 TP73 TP53 PTEN CDKN2A
5 12.24 TP53 CDKN2C CDKN2B CDKN2A
6 12.24 TP53 CDKN2C CDKN2B CDKN2A
7
Show member pathways
12.22 TP53 CDKN2C CDKN2B CDKN2A
8 12.21 TP73 TP53 MGMT GMNN CDKN2C CDKN2A
9 12.03 TP53 PTEN CDKN2B CDKN2A
10 11.92 TP73 TP53 PTEN EGFR
11 11.86 TP53 MBP GFAP EGFR
12 11.82 TP73 TP53 PTEN CDKN2A
13 11.76 TP53 PTEN CDKN2B
14 11.74 OLIG2 OLIG1 MBP GFAP
15 11.62 TP53 EGFR CDKN2A
16 11.6 TP53 PTEN MGMT EGFR CDKN2A
17 11.54 TP53 PTEN ATRX
18 11.46 TP53 PTEN IDH1 EGFR
19 11.42 TP53 EGFR CDKN2A
20 11.35 TP53 PTEN CDKN2B
21 10.92 SYP OLIG2 OLIG1 NKX2-2 GFAP
22
Show member pathways
10.89 TP73 TP53 CDKN2A
23 10.76 TP53 CDKN2C CDKN2B CDKN2A
24
Show member pathways
10.73 IDH2 IDH1

GO Terms for Oligodendroglioma

Cellular components related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 TP73 TP53 PTEN POT1 NKX2-2 MGMT
2 nucleus GO:0005634 9.53 TP73 TP53 PTEN POT1 OLIG2 OLIG1
3 PML body GO:0016605 9.33 TP53 PTEN ATRX

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 TP53 PTEN CDKN2C CDKN2B CDKN2A
2 cell cycle GO:0007049 9.93 TP73 TP53 GMNN CDKN2C CDKN2B CDKN2A
3 G1/S transition of mitotic cell cycle GO:0000082 9.76 GMNN CDKN2C CDKN2A
4 negative regulation of neuron differentiation GO:0045665 9.7 TP73 OLIG2 NKX2-2
5 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.67 PTEN CDKN2C CDKN2B
6 replicative senescence GO:0090399 9.58 TP53 CDKN2A
7 negative regulation of telomerase activity GO:0051974 9.57 TP53 POT1
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.56 TP53 EGFR
9 NADP metabolic process GO:0006739 9.55 IDH2 IDH1
10 oligodendrocyte differentiation GO:0048709 9.54 OLIG2 OLIG1 CDKN2C
11 isocitrate metabolic process GO:0006102 9.48 IDH2 IDH1
12 spinal cord oligodendrocyte cell fate specification GO:0021530 9.43 OLIG2 NKX2-2
13 positive regulation of oligodendrocyte differentiation GO:0048714 9.43 TP73 OLIG2 NKX2-2
14 spinal cord oligodendrocyte cell differentiation GO:0021529 9.4 OLIG2 NKX2-2
15 cell cycle arrest GO:0007050 9.35 TP73 TP53 CDKN2C CDKN2B CDKN2A
16 negative regulation of phosphorylation GO:0042326 9.33 CDKN2C CDKN2B CDKN2A
17 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
18 response to organic cyclic compound GO:0014070 9.02 PTEN NKX2-2 MGMT IDH1 EGFR
19 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 TP73 TP53 NKX2-2 EGFR CDKN2B CDKN2A

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.95 TP73 TP53 SYP PTEN IDH1 GFAP
2 chromatin binding GO:0003682 9.63 TP53 NKX2-2 GMNN EGFR CIC ATRX
3 isocitrate dehydrogenase activity GO:0004448 9.32 IDH2 IDH1
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1
5 protein kinase binding GO:0019901 9.17 TP73 TP53 PTEN EGFR CDKN2C CDKN2B
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CDKN2C CDKN2B CDKN2A
7 DNA binding GO:0003677 10.07 TP73 TP53 POT1 OLIG2 OLIG1 NKX2-2

Sources for Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....